Quanterix Corp (NASDAQ:QTRX) Chairman E Kevin Hrusovsky sold 2,829 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $17.97, for a total value of $50,837.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
E Kevin Hrusovsky also recently made the following trade(s):
- On Tuesday, October 2nd, E Kevin Hrusovsky sold 2,995 shares of Quanterix stock. The shares were sold at an average price of $20.91, for a total value of $62,625.45.
- On Wednesday, September 5th, E Kevin Hrusovsky sold 17,909 shares of Quanterix stock. The shares were sold at an average price of $14.53, for a total value of $260,217.77.
NASDAQ QTRX traded down $0.84 during trading hours on Monday, reaching $16.65. 63,600 shares of the stock traded hands, compared to its average volume of 100,096. Quanterix Corp has a 1 year low of $13.00 and a 1 year high of $24.81. The company has a market capitalization of $386.52 million and a price-to-earnings ratio of -2.02.
Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Friday, August 10th. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.06). The business had revenue of $8.64 million during the quarter, compared to analyst estimates of $7.92 million. Analysts expect that Quanterix Corp will post -1.2 earnings per share for the current year.
A number of equities research analysts have weighed in on the company. Zacks Investment Research upgraded Quanterix from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. Canaccord Genuity assumed coverage on Quanterix in a research report on Wednesday, October 10th. They set a “buy” rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $26.67.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gilder Gagnon Howe & Co. LLC raised its position in Quanterix by 54.2% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,090,893 shares of the company’s stock valued at $15,665,000 after purchasing an additional 383,602 shares in the last quarter. Royce & Associates LP increased its holdings in shares of Quanterix by 83.6% in the second quarter. Royce & Associates LP now owns 479,000 shares of the company’s stock worth $6,878,000 after buying an additional 218,115 shares during the period. Jennison Associates LLC increased its holdings in shares of Quanterix by 1.8% in the second quarter. Jennison Associates LLC now owns 351,831 shares of the company’s stock worth $5,052,000 after buying an additional 6,170 shares during the period. BlackRock Inc. increased its holdings in shares of Quanterix by 22.1% in the second quarter. BlackRock Inc. now owns 246,466 shares of the company’s stock worth $3,539,000 after buying an additional 44,662 shares during the period. Finally, Bellevue Group AG increased its holdings in shares of Quanterix by 97.5% in the second quarter. Bellevue Group AG now owns 165,480 shares of the company’s stock worth $2,376,000 after buying an additional 81,680 shares during the period. Institutional investors and hedge funds own 49.14% of the company’s stock.
WARNING: “Insider Selling: Quanterix Corp (QTRX) Chairman Sells 2,829 Shares of Stock” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/05/insider-selling-quanterix-corp-qtrx-chairman-sells-2829-shares-of-stock.html.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Featured Article: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.